SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 14th, 2023 • Taysha Gene Therapies, Inc. • Biological products, (no disgnostic substances) • New York
This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of August 14, 2023, is made by and among TAYSHA GENE THERAPIES, INC., a Delaware corporation (the “Company”), and the Purchasers listed on Schedule 1 hereto, together with their permitted transferees (each, a “Purchaser” and collectively, the “Purchasers”).
PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK TAYSHA GENE THERAPIES, INC.Taysha Gene Therapies, Inc. • August 14th, 2023 • Biological products, (no disgnostic substances)
THIS PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [•] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”), to subscribe for and purchase from TAYSHA GENE THERAPIES, INC., a Delaware corporation (the “Company”), up to [•] shares of common stock, par value $0.00001 per share (the “Common Stock”) (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
